氢氯吡格雷联合辛伐他汀治疗急性冠状动脉综合征的疗效观察

目的探讨氢氯吡格雷与辛伐他汀治疗急性冠状动脉综合征(ACS)的临床效果。方法将2007年1月至2010年5月期间在贵州省清镇市第一人民医院治疗的58例ACS患者随机分为观察组和对照组,对照组给予常规治疗措施,观察组同时给予氢氯吡格雷与辛伐他汀联合治疗措施。结果治疗后观察组患者在血清hs-CRP改善方面明显优于对照组,两组比较差异具有显著性(P<0.05);观察组与对照组血脂改善情况比较差异无显著性(P>0.05)。治疗后观察组血小板聚集率为(38.72±2.22)%,对照组血小板聚集率为(43.75±2.23)%,观察组患者血小板聚集率明显低于对照组,两组比较差异具有显著性(P<0.05)。观察组出现恶心呕吐l例,对照组出现恶心呕吐2例。无其他明显副作用。结论辛伐他汀合并氯吡格雷可通过提高内皮功能,抑制炎症等非降脂作用来发挥治疗急性冠状动脉综合征,值得临床推广。

Hydrogen Clopidogrel Joint Simvastatin Treatment of Acute Coronary Syndrome Clinical Observation

Objective To study the hydrogen clopidogrel and simvastatin in treatment of acute coronary syndrome （ACS） clinical effect.Methods From January 2007 in May 2010 during the treatment in our hospital from 58 cases of ACS patients were randomly divided into trial group and control group,the control group,conventional treatment measures to observation group also give hydrogen clopidogrel and simvastatin joint treatment measures.Results After treatment,patients with the observation group in serum hs-CRP improvement was better than control,two groups of comparisons with significant difference （P0.05）.The observation group and control group lipid improve conditions are no significant difference （P0.05）.After treatment,the observation group platelet aggregation rate for （38.72±2.22） %,platelet aggregation rate control for （43.75±2.23） %,the observation group patients platelet aggregation rate obviously lower than those of the control group,two groups of comparisons with significant difference （P0.05）.The observation group nausea vomiting l cases and control nausea vomiting in 2 cases.No other obvious side effects.Conclusion Simvastatin merger clopidogrel can inhibit endothelial function,by raising the lipid-lowering role as inflammation in the treatment of acute coronary syndrome to play,worth clinical promotion.